The identification of combinations for the CDK4 and CDK6 inhibitor, abemaciclib

被引：0
|
作者：
Gong Xueqian
Chio, Li-Chun
Webster, Yue
Lallena, Maria Jose
Boehnke, Karsten
Torres, Raquel
Iversen, Phil
De Dios, Alfonso
Smith, Ian
Reinhard, Christoph
Peng, Sheng-Bin
Dempsey, Jack
Burke, Teresa
Chen, Shih-Hsun
Stewart, Trent
Beckmann, Richard
Wu, Wenjuan
Buchanan, Sean G.
机构：
来源：
MOLECULAR CANCER RESEARCH | 2016年 / 14卷
关键词：
D O I：
10.1158/1557-3125.CELLCYCLE16-A07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A07
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Clinical Activity of Abemaciclib (LY2835219), a Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Relapsed or Refractory Mantle Cell Lymphoma
    Morschhauser, Franck
    Bouabdallah, Kamal
    Stilgenbauer, Stephan
    Thieblemont, Catherine
    Wolf, Martin
    de Guibert, Sophie
    Zettl, Florian
    Hahka-Kemppinen, Marjo
    Wang, David Xiaohui
    Brueck, Patrick
    Caldwell, Charles
    Beckmann, Richard
    Gelbert, Lawrence
    Cronier, Damien
    Lin, Ji
    Li, Lily
    Chan, Edward M.
    Pfreundschuh, Michael
    Wilhem, Martin
    Hess, Georg
    [J]. BLOOD, 2014, 124 (21)
  • [32] A NOVEL SUBSTRATE FOUND IN EPITHELIAL TYPE CELLS FOR CDK4 AND CDK6
    KWON, TK
    BUCHHOLZ, M
    GABRIELSON, E
    NORDIN, A
    [J]. FASEB JOURNAL, 1995, 9 (04): : A1066 - A1066
  • [33] CDK6 might be a key factor for efficacy of CDK4/6 inhibitor and the hormone sensitivity following acquired resistance
    Iida, Masafumi
    Nakamura, Misato
    Tokuda, Emi
    Niwa, Toshifumi
    Ishida, Takanori
    Hayashi, Shin-ichi
    [J]. CANCER RESEARCH, 2018, 78 (04)
  • [34] Inducible deletion of CDK4 and CDK6-deciphering CDK4/6 inhibitor effects in the hematopoietic system
    Maurer, Barbara
    Brandstoetter, Tania
    Kollmann, Sebastian
    Sexl, Veronika
    Prchal-Murphy, Michaela
    [J]. HAEMATOLOGICA, 2021, 106 (10) : 2624 - 2632
  • [35] A narrative review of the clinical development of CDK4/6 inhibitor abemaciclib in breast cancer
    Yang, Liu
    Chen, Yang
    Wang, Ning
    Han, Weiwei
    [J]. TRANSLATIONAL BREAST CANCER RESEARCH, 2022, 3
  • [36] Tumor resistance to CDK4/6 inhibitors and degraders determined by the expression state of CDK6
    Wu, Xuewei
    Yang, Xiaobao
    Xiong, Yan
    Li, Ruitong
    Ito, Takahiro
    Ahmed, Tamer
    Karoulia, Zoi
    Adamopoulos, Christos
    Wang, Hong
    Wang, Li
    Xie, Ling
    Ueberheide, Beatrix
    Aaronson, Stuart
    Chen, Xian
    Sellers, William
    Buchanan, Sean
    Jin, Jian
    Poulikakos, Poulikos I.
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [37] Distinct roles for Cdk4 and Cdk6 during B lymphocyte activation.
    Tanguay, DA
    Chiles, TC
    [J]. FASEB JOURNAL, 1996, 10 (06): : 120 - 120
  • [38] IDENTIFICATION OF HUMAN AND MOUSE P19, A NOVEL CDK4 AND CDK6 INHIBITOR WITH HOMOLOGY TO P16(INK4)
    CHAN, FKM
    ZHANG, JK
    CHENG, L
    SHAPIRO, DN
    WINOTO, A
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1995, 15 (05) : 2682 - 2688
  • [39] Alteration in the expression of cdk4 and cdk6 proteins in oral cancer and premalignant lesions
    Poomsawat, Sopee
    Buajeeb, Waranun
    Khovidhunkit, Siribang-on
    Punyasingh, Jirapa
    [J]. JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2010, 39 (10) : 793 - 799
  • [40] Discovery of mechanisms that modulate the hippo pathway and CDK6 expression in CDK4/6 inhibitor resistant breast cancer cells
    Yu, Chung-Jen
    Zhuang, Yong-Ji
    Lin, Ting-Yi
    Chao, Ta-Chung
    Liu, Chun-Yu
    Tseng, Ling-Ming
    Lai, Jiun-I
    [J]. CANCER RESEARCH, 2023, 83 (07)
12345